These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 8552873)

  • 1. [Hematologic changes associated with infection of mice by Cryptococcus neoformans].
    Velasco-Lezama R; Tapia-Aguilar R; Luna-Acevedo P; Cruz-Islas E; Garza-Garza D
    Rev Latinoam Microbiol; 1995; 37(2):135-46. PubMed ID: 8552873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contributions to the strain-specific virulence of Cryptococcus neoformans. Animal experiments with two C. neoformans-strains isolated from bird manure. Preliminary report (author's transl)].
    Staib F; Mishra SK
    Zentralbl Bakteriol Orig A; 1975 Jan; 230(1):81-5. PubMed ID: 1101575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcus neoformans capsule structure evolution in vitro and during murine infection.
    Garcia-Hermoso D; Dromer F; Janbon G
    Infect Immun; 2004 Jun; 72(6):3359-65. PubMed ID: 15155641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis.
    Barchiesi F; Cogliati M; Esposto MC; Spreghini E; Schimizzi AM; Wickes BL; Scalise G; Viviani MA
    J Infect; 2005 Jul; 51(1):10-6. PubMed ID: 15979484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.
    Huffnagle GB; Toews GB; Burdick MD; Boyd MB; McAllister KS; McDonald RA; Kunkel SL; Strieter RM
    J Immunol; 1996 Nov; 157(10):4529-36. PubMed ID: 8906831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia.
    Chrétien F; Lortholary O; Kansau I; Neuville S; Gray F; Dromer F
    J Infect Dis; 2002 Aug; 186(4):522-30. PubMed ID: 12195380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of Cryptococcus neoformans strains isolated from patients with acquired immunodeficiency syndrome (AIDS)].
    Garza-Garza D; Buendía-Uribe JL; Martínez-Cruz E; Argüero-Licea B
    Rev Latinoam Microbiol; 1995; 37(3):273-9. PubMed ID: 8850346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcus neoformans meningitis in the rat.
    Goldman DL; Casadevall A; Cho Y; Lee SC
    Lab Invest; 1996 Dec; 75(6):759-70. PubMed ID: 8973471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
    Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
    Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production.
    Kawakami K; Qureshi MH; Zhang T; Okamura H; Kurimoto M; Saito A
    J Immunol; 1997 Dec; 159(11):5528-34. PubMed ID: 9548493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of Cryptococcus neoformans on uric acid agar.
    Staib F; Mishra SK; Able T; Blisse A
    Zentralbl Bakteriol Orig A; 1976 Nov; 236(2-3):374-85. PubMed ID: 797180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
    Feldmesser M; Casadevall A
    J Immunol; 1997 Jan; 158(2):790-9. PubMed ID: 8992996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans.
    Huffnagle GB; McNeil LK; McDonald RA; Murphy JW; Toews GB; Maeda N; Kuziel WA
    J Immunol; 1999 Nov; 163(9):4642-6. PubMed ID: 10528159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain.
    Wormley FL; Cox GM; Perfect JR
    Microb Pathog; 2005; 38(2-3):113-23. PubMed ID: 15748813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection.
    Aguirre K; Miller S
    Glia; 2002 Aug; 39(2):184-8. PubMed ID: 12112369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Cryptococcus neoformans infection in an asplenic patient.
    Qazzafi Z; Thiruchunapalli D; Birkenhead D; Bell D; Sandoe JA
    J Infect; 2007 Dec; 55(6):566-8. PubMed ID: 17905439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fungemia during murine cryptococcosis sheds some light on pathophysiology.
    Lortholary O; Improvisi L; Nicolas M; Provost F; Dupont B; Dromer F
    Med Mycol; 1999 Jun; 37(3):169-74. PubMed ID: 10421848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathogenicity of Crytococcus albidus].
    Wieser HG
    Schweiz Med Wochenschr; 1973 Mar; 103(13):475-81. PubMed ID: 4572957
    [No Abstract]   [Full Text] [Related]  

  • 20. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier.
    Charlier C; Chrétien F; Baudrimont M; Mordelet E; Lortholary O; Dromer F
    Am J Pathol; 2005 Feb; 166(2):421-32. PubMed ID: 15681826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.